increase in TBR for the non-ADHD groups. A substantial sub-group of ADHD patients
do deviate on the TBR measure, but excessive TBR is not a reliable diagnostic measure
of ADHD. It may have prognostic value. (Arns M, et al. A decade of EEG theta/beta ratio

COMMENTARY. The FDA approved the Neuropsychiatric EEG-Based ADHD
Assessment Aid (NEBA) medical device in 2013 to be used as confirmatory support or to
pursue further testing after an evaluation for ADHD, in a child aged 6-17. The device was
not to be used as a stand alone method of diagnosis of ADHD.

The AAN, in an Evidence-Based Practice Advisory, concludes that it is highly
likely that EEG theta-beta power ratio and EEG frontal beta power correctly identify
patients with ADHD (accuracy 89% to 94%) as compared to a clinical evaluation. The
AAN recommends that the EEG test should not be used in place of a standard clinical
evaluation, because of the risks of misdiagnosis of 6-15% when using the theta/beta ratio.
There is neither evidence for, nor against the use of theta/beta EEG power ratio either to
confirm a diagnosis of ADHD, nor to support further testing. Whether comorbid
disorders such as ODD have similar changes in the theta/beta ratios that mimic the
reported finding in ADHD is not known [1].

A recent report of spectral analysis of EEGs on 28 normal and 58 ADHD
children, aged 6 to 14 years, found TBR was higher in ADHD subjects, with lower beta
but no difference in theta power over Broca’s area. Beta-1 power over Broca’s area was
the best diagnostic test, with sensitivity 0.86 and specificity 0.57. The EEG beta-1 power
and TBR assist in confirming the diagnosis of ADHD in a sample with moderate pretest
probability of ADHD [2].

The present symptomatic method of diagnosis, based on parent and teacher
evaluations, is relatively accurate in children with the hyperactive-impulsive subtype of
ADHD but less so with the inattentive type. A more objective test such as EEG if
validated could be a valuable aid in the diagnosis and management of ADHD. The
significance of seizure discharges in approximately 25% of sleep-deprived EEGs in
ADHD children is further evidence of the utility of the EEG in ADHD management [3].

References.

TREATMENT OF ADHD

EFFECT OF METHYLPHENIDATE ON INATTENTION DURING DRIVING

Investigators at Utrecht University, the Netherlands; and centers in Australia and
Detroit, MI, evaluated the lapses of attention during on-road highway driving in 18 adult
ADHD patients during treatment with methylphenidate (MPH) or placebo. Driving was
significantly better with MPH when compared with placebo, with reduction in weaving,
lapses, and inattention. Lapses were common on placebo (11/18 patients), and much less
after MPH (5/18). Lapses often go unnoticed by drivers. (Verster JC, Roth T. 
Methylphenidate significantly reduces lapses of attention during on-road highway driving in patients with ADHD. J Clin Psychopharmacol 2014 Jun 27. [Epub ahead of print]).

COMMENTARY. ADHD young adults are twice as likely to be cited for unlawful speeding and have more crashes and more accidents involving bodily injury, when compared to non-ADHD adult control subjects. These findings support a need for continued treatment of ADHD into adolescence and adulthood. Improvement of driving performance of adolescent drivers with ADHD was demonstrated using a driving simulator while taking Concerta compared to placebo [1] or immediate-release MPH [2].

References.

GUANFACINE EXTENDED RELEASE IN ADHD

Investigators at Massachusetts General Hospital, Boston, MA, performed a multicenter, 9-week, double-blind, placebo-controlled, dose-optimization study of guanfacine extended release (GXR, <4 mg/d) adjunctive to a long-acting psychostimulant for ADHD continued in 461 subjects. Patients were randomized to receive GXR in the morning (GXR AM), GXR in the evening (GXR PM), or placebo.

GXR treatment groups showed significantly greater improvement from baseline compared with placebo plus psychostimulant. Small mean decreases in pulse, systolic, and diastolic blood pressure were observed in GXR treatment groups. Morning or evening GXR administered adjunctively to a psychostimulant showed significantly greater improvement and generated no new safety signals. (Wilens TE, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 2012;51(1):74-85).

COMMENTARY. A similar randomized, double-blind trial of guanfacine extended release (Intuniv) administered either in the morning (n=107) or evening (n=114) was associated with significant improvements in ADHD symptoms. Once-daily GXR monotherapy is effective, administered AM or PM [1]. The rapid-release guanfacine (Tenex) is often prescribed as an alternative to Intuniv because of cost and insurance denial. Tenex is often effective in the hyperactive/ADHD younger child with sleep disorder or tics, but drowsiness during the day may lessen the ability to focus in school. The effect of Intuniv on school performance and grades requires further study.

References.

ADVERSE EFFECTS OF MEDICATIONS FOR ADHD

CARDIAC AUTONOMIC DYSFUNCTION AND STIMULANT THERAPY

Investigators at University of Minnesota, Minneapolis, report cardiac autonomic dysfunction and arterial stiffness among children and adolescents with ADHD treated